Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

One month has passed since the Democratic Republic of the Congo (DRC) declared its 17th Ebola outbreak, and there is no sign of respite. Confirmed cases and deaths have surged to 808 and 192, respectively, according to the country's Health Ministry.

Uganda has confirmed 19 infections, while Congo's Ituri province, where the outbreak first emerged, accounts for more than 90% of cases in the country.

The outbreak was reported to the World Health Organization (WHO) and the outbreak was officially declared on May 15.

The cases continue to surge daily as health authorities and aid agencies grapple with inadequate testing, weak contact tracing, and community resistance.

However, experts warn the outbreak's true scale may be far greater than official data indicate, making it already the third-deadliest Ebola outbreak on record.

Ebola Epidemic Moving Upward

Also read: Ebola Survivors May Face COVID-Like Memory Loss and Brain Issues For Over 7 Years: NIH Study

According to Dieudonne Mwamba Kazadi, head of the DRC National Institute of Public Health (INSP), the Ebola epidemic was still moving upward in Bunia, the capital of Ituri province and the epicenter of the outbreak, Xinhua News Agency reported.

"We are still in the midst of the epidemic. I would say we are in the upward phase of the outbreak, the active phase," Kazadi said.

More confirmed cases are expected in the coming days, making it urgent to expand treatment capacity and establish new Ebola treatment centers in affected areas, he noted.

"The perspective is really to increase capacity and already have treatment centers positioned to receive the future suspected and confirmed cases that we will identify in the coming days and weeks," Kazadi said, stressing the need to "engaging communities further," he said.

True Scale of Outbreak Remains Unclear

Read More: Expert Explains Science Behind Ebola Patient Recoveries

Medical charity Medecins Sans Frontieres (MSF) said in a statement that the government's figures likely understate the true toll of the outbreak, echoing concerns raised by aid groups and some Congolese officials.

"No one knows the true scale or exactly where the disease is spreading in DRC," said Kate White, MSF's emergency medical coordinator.

"One month on, the Ebola disease outbreak is outpacing the response effort," White said.

She noted that most treatment centers in Ituri province are overwhelmed, with many patients arriving at a late stage of the disease.

"What we do know is that most treatment centers in Ituri province are overwhelmed; many of our patients arrive at a late stage of the disease, and the majority were never identified or monitored as contacts before seeking care," White said.

Testing and Contact Tracing Challenges

Testing remains "one of the most significant weaknesses in the response," according to the MSF statement.

WHO Director-General Tedros Adhanom Ghebreyesus said he was “really worried” about the outbreak after visiting the DRC, Stat News reported.

“When the community is not taking it as its priority, it’s very hard,’’ Tedros said. He said that in the North Kivu, South Kivu, and Ituri provinces where the outbreak is centered, Ebola is seen as a lesser evil compared with armed conflict, widespread hunger, and more common deadly diseases experienced daily.

Notably, many communities, particularly those affected by active armed conflict, still lack access to test kits. Treatment centers are also facing significant delays in receiving laboratory results, hampering efforts to quickly identify and isolate infections.

What Is Ebola?

Ebola is a highly lethal viral hemorrhagic fever first identified in 1976. Over the past five decades, it has caused over 30 outbreaks, primarily in Central and West Africa.

Symptoms include fever, headache, weakness, vomiting, diarrhea, muscle pain, sore throat, and unexplained bleeding. This eventually leads to severe complications like bleeding, organ failure, and death.

Aid groups warn that without stronger surveillance, faster testing, and improved contact tracing, the outbreak could continue to expand in the weeks ahead.

The United Kingdom is planning to create a new normal for children by banning social media for kids under 16. The services of social media, including Instagram and Snapchat, will not be available for adolescents in the island nation. The government there is planning to follow in the steps of Australia and block social media to ensure a safe and secure childhood.

To better protect children online and tackle growing digital risks, the government plans to introduce measures that go beyond a simple social media ban. Under the proposal, children under 16 would be blocked from accessing high-risk features such as livestreaming and communicating with strangers online. These world-leading restrictions would extend beyond social media platforms to cover a broader range of online services, including gaming websites, making the policy one of the most comprehensive child online safety measures introduced anywhere in the world.

Prime Minister Keir Starmer said, Parents want to keep their kids safe and happy, but the online world has made that harder than ever." He added, "I’ve heard firsthand from families crying out for change, and we will do right by them."

He also said that any country can ban social media for under-16s and put wider protections in place to give kids their childhood back.

Other Countries That Are Planning To Implement Social Media Ban

• Denmark: Plans to ban social media for children under 15, with limited parental exceptions for those aged 13–14.
• France: Approved a bill to ban social media for children under 15, pending final legislative approval.
• India: Karnataka has banned social media for children under 16. Other states like Andhra Pradesh, Goa, and Bihar are considering age restrictions.
• Italy: Children under 14 need parental consent to create social media accounts.
• Poland: Drafted legislation to ban social media for children under 15 and require age verification.
• Slovenia: Preparing a law that would prohibit social media access for children under 15.
• Spain: Plans to ban social media access for minors under 16 and require age verification.
• Sweden: A government commission has recommended a minimum social media age of 15.
• United States: Several states require parental consent for minors, while federal legislation seeks stronger protections for young users.
• European Union: Considering stricter child safety rules, including parental consent for under-16s and a ban for children under 13.

Which Countries Have Already Banned Or Imposed Curbs On Social Media Use By Children?

There are several nations that have already banned or implemented significant mechanisms to curb social media use by children. Australia, Malaysia, and Turkey have already passed laws to ban social media for children. On the other hand, China and Greece have made arrangements to curb the use of social media by children.

The dengue virus is rapidly shifting serotypes, especially in young adults. The phenomenon is not unique to India and has been observed in several dengue-endemic countries across Asia, Latin America, and parts of the Pacific.

Dengue is caused by four closely related virus serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. The dominant serotype in circulation can change over time, leading to new outbreaks when population immunity is low against the emerging strain.

A 2026 genomic study, published in the international journal Acta Tropica, found that DENV-2 and DENV-3 were the most common serotypes between 2019 and 2024 in South India, with dominance shifting every 2–3 years. The authors, including those from the Indian Institute of Science, Bengaluru, highlighted the importance of monitoring these shifts because they can alter outbreak severity and vaccine effectiveness.

A 2025 study led by researchers from AIIMS Bhopal reported the emergence of a new DENV-2 lineage that displaced the previously dominant DENV-1 strain between 2019 and 2023. The findings, published in the journal Viruses, demonstrated how one serotype can replace another in a population.

“India is witnessing active serotype shifts, and they directly explain rising severity, especially in young adults. Initial infection with one of the four dengue serotypes results in lifelong immunity to that specific serotype. Whereas, a secondary infection with a different serotype can trigger Antibody-Dependent Enhancement (ADE),” Dr. Shikha Taneja Malik, Senior Scientific Affairs Manager, Drugs for Neglected Diseases initiative (DNDi), South Asia, told HealthandMe.

“Young adults who were exposed to one serotype in childhood are now encountering a new dominant serotype, making them especially vulnerable to severe secondary infections,” she added.

The four serotypes of dengue virus makes it a difficult virus; and protection against one does not always mean balanced protection against all.

"In young adults, this becomes even more important because many may have already been exposed to one dengue serotype earlier in life, while later infections may involve a different or shifting virus serotype. This can make the immune response more complex and, in some cases, may increase the risk of severe disease through antibody-dependent enhancement," Dr. Rohit Sharma, Consultant, Apollo Spectra Hospital, Jaipur, told HealthandMe.

Shifting Serotypes: A Global Trend Beyond India

Researchers have also documented a gradual shift in disease burden from children toward adolescents and young adults in some regions. This occurs because:

• Previous exposure patterns change over time.
• Urbanization increases transmission among older age groups.
• Childhood immunity profiles evolve as dominant serotypes change.
• Secondary infections with a different serotype can increase the risk of severe disease.

India's Indigenous Dengue Vaccine: DengiAll

DengiAll is India's first indigenous tetravalent dengue vaccine. Developed by the Indian pharmaceutical company Panacea Biotec, it is designed to protect against all four serotypes of the dengue virus and requires only a single dose.

The indigenously developed dengue vaccine is expected to play a crucial role in protecting the 10–20 age group, who are most susceptible to severe dengue cases, Dr. N. K. Arora, Member of the National Technical Advisory Group on Immunisation in India (NTAGI), told HealthandMe.

"Most dengue infections are mild, and treatment protocols have improved significantly over the years. However, the disease can become severe, particularly among adolescents and young adults aged 10–20 years. This is why the indigenous dengue vaccine is being eagerly awaited, as it has the potential to provide an important layer of protection for this vulnerable age group," he said.

The vaccine expert noted that the indigenous dengue vaccine is currently undergoing trials.

“The trials will take at least two and a half years, which means by the end of 2028, we will have the results,” Dr. Arora said.

Brazil's Vaccine Setback Raises Questions for India

Also read: Dengue Is Spreading Beyond Monsoons And Into New Regions Across India, Says Expert

Meanwhile, Brazil has suspended its Butantan-DV dengue vaccine after the death of two people who received the shot, which was proven to be over 80 percent effective in preventing the risk of severe disease for up to five years

This suspension, announced on June 8, is a crucial wake-up call for India, said experts, as the Butantan-DV is pretty similar, if not identical, to DengiAll. Both are also based on the same core viral strains developed by the US National Institutes of Health (NIH),

"Brazil’s recent experience with its dengue vaccination campaign should be viewed as an important safety signal for India, especially as India prepares for the possible rollout of DengiAll," Dr. Rohit said.

"Before any large-scale rollout, India must carefully study whether the vaccine produces strong type-specific protection against all four serotypes and whether there is any risk of imbalance in immunity," he added.

A dengue vaccine can be a major public health tool, but it must be supported by transparent data, long-term safety monitoring, and region-wise surveillance of circulating dengue serotypes, the experts said.